NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

The National Institute for Care and Excellence (NICE) has announced that it has recommended an oral treatment for the prevention of episodic migraines for the first time, leading to a new treatment option for around 145,000 patients accessing NHS England.

Pfizer’s rimegepant (Vydura) is designed as a wafer that dissolves when placed under the tongue and works by stopping the release of a protein around the brain that is responsible for the pain associated with migraines. It is recommended for people who have at least four migraine attacks per month, but less than 15.

Current treatment options include beta blockers, antidepressants and epilepsy medication, all of which are used for other conditions. These frequently cause significant side effects and can be ineffective for some patients. Treatments offered after these are NICE-recommended injections erenumab, fremanezumab or galcanezumab. […]

The post NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks appeared first on Pharmafile.